675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
2026 Stock Incentive Plan Approved by Spero Therapeutics Stockholders
Utebzi approved in the US for adults with complicated urinary tract infections (cUTIs)
Announces First Quarter 2026 Operating Results and Provides Business Update
Annual Report to Security Holders
Financial Results, Press Release
Material disclosure
GSK Files NDA Resubmission for Tebipenem HBr; $25M Milestone Payment Triggered
Announces Third Quarter 2025 Operating Results and Provides a Business Update
Q1
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order